|
English
|
正體中文
|
简体中文
|
2818662
|
|
???header.visitor??? :
28176900
???header.onlineuser??? :
684
???header.sponsordeclaration???
|
|
|
|
???tair.name??? >
???browser.page.title.author???
|
"tay m h"???jsp.browse.items-by-author.description???
Showing items 1-4 of 4 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 臺大學術典藏 |
2022-08-19T00:20:47Z |
A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma
|
Tak W.Y.; Yen C.-J.; Jeffers M.; Krissel H.; Kappeler C.; Rajagopalan P.; Hsieh W.-S.; Tay M.H.; Yeo W.; Park J.-W.; Poon R.T.P.; Rau K.-M.; CHIUN HSU; Yoon J.-H.; Lin C.-Y.; Choi H.J.; Heo J.; Lim H.Y. |
| 臺大學術典藏 |
2020-05-25T07:35:21Z |
RECORD-2: Phase II randomized study of everolimus and bevacizumab versus interferon �\-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma
|
Ravaud A; Barrios C.H; Alekseev B; Tay M.-H; Agarwala S.S; Yalcin S; Chia-Chi Lin; Roman L; Shkolnik M; Anak O; Gogov S; Pelov D; Louveau A.-L; Melichar B. |
| 臺大學術典藏 |
2020-04-10T12:51:06Z |
A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma
|
Lim H.Y.; Heo J.; Choi H.J.; Lin C.-Y.; Yoon J.-H.; Chiun Hsu; Rau K.-M.; Poon R.T.P.; Yeo W.; Park J.-W.; Tay M.H.; Hsieh W.-S.; Kappeler C.; Rajagopalan P.; Krissel H.; Jeffers M.; Yen C.-J.; Tak W.Y. |
| 國立臺灣大學 |
2015 |
Phase 3 study of radium-223 dichloride (Ra-223) in Asian patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets)
|
Sun, Y.; Shi, H.; Chen, C. -H.; Lee, J. L.; Kang, T. W.; Park, S. H.; Wu, T. L.; Ng, Q. S.; Keam, B.; Wong, S. C. A.; Tay, M. H.; Ding, Q.; Li, F.; Ng, D. C. E.; Liu, X.; Zhang, Z.; Guo, J.; 陳忠信 |
Showing items 1-4 of 4 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
